What would you guess is the world’s most neglected disease? I bet that you wouldn’t pick tuberculosis (TB)— a disease that causes an estimated 9 million new cases and 1.3 million deaths annually. This infectious disease is caused by the bacterium Mycobacterium tuberculosis. TB usually attacks the lungs, but can attack any part of the body. […]Read More
Author: David Hermann
David Hermann is a Vice President and Lead Scientist at Certara. Over the past 20 years, Dr Hermann has has been a champion of model-based drug development serving both large and small pharmaceutical companies. After receiving his Pharm.D. from the University of Illinois in 1988, Dr. Hermann completed a two-year fellowship in Clinical Research and Drug Development supported by the University of North Carolina and Glaxo. He then held various positions of increasing responsibility within the Clinical Pharmacology Division at Glaxo. Responsibilities included representing Clinical Pharmacology on global project teams, leading early clinical development teams, crafting clinical development and dose selection strategies and providing regulatory agency support. Then as a Pharsight consultant, Dr Hermann was responsible for devising and conducting Computer Trial Simulation projects and Modeling and Simulation training programs. While at Pharsight, he co-authored a patent titled “Interactive Graphical Environment for Drug Model Generation”. In 2001, Dr. Hermann joined Pfizer as Director of Pharmacometrics where he remained focused on applying pharmacologically based modeling and simulation techniques to aid decision making as well as assessing and implementing new model-based technologies such as Pharsight’s Drug Model Explorer. In 2005, Dr Hermann received the BIO-IT World Grand Prize award for “Best Practices in Computational Biology and Informatics” for modeling and simulation work he lead while at Pfizer. He then joined deCODE genetics where his responsibilities included managing the Clinical Pharmacology and Biostatistics groups. In 2008, Dr Hermann co-founded Great Lakes Drug Development, a strategic drug development consultancy where he served as CEO and Head of Pharmacometrics. In 2013, he joined the Certara team as Vice President and Lead Scientist, Pharsight Consulting Services.